iX Biopharma Secures SGX Listing Approval for S\$5 Million Placement: What Investors Need to Know Now

Key Developments in iX Biopharma’s Strategic Capital Raise

iX Biopharma Ltd. has announced a significant milestone in its latest capital raising initiative. The company has received the Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) approving the listing and quotation of up to 67,000,000 new shares as part of its proposed placement to raise no less than S\$5,000,000 in gross proceeds.

What This Means for Shareholders and Investors

• Placement Agreement: The placement is being executed through Oversea-Chinese Banking Corporation Limited, indicating a strong institutional backing for the capital raise.
• SGX-ST Approval: The LQN received on 30 October 2025 signals regulatory acceptance for the listing of new shares, subject to ongoing compliance with SGX-ST listing requirements.
• Potential Share Price Impact: The issuance of up to 67 million new shares could lead to share dilution, which is a critical consideration for existing shareholders. While this may affect the share price in the short term, the infusion of new capital could strengthen the company’s balance sheet and fund future growth initiatives.
• Conditions and Uncertainties: The placement is still subject to the fulfilment of conditions set out in the Placement Agreement. Shareholders should note that completion is not guaranteed until all conditions are met.
• Ongoing Updates: The company has committed to keeping shareholders informed of all material developments relating to the placement, including progress and any changes to the terms or status of the deal.

Important Considerations and Risks

Shareholders and potential investors are advised to exercise caution when trading in iX Biopharma shares during this period of corporate action. The placement is contingent on various conditions, and there may be market volatility as the transaction progresses. If you are uncertain about the implications, consult legal, financial, tax, or other professional advisers.

Contact Information for Investor Queries

The company’s sponsor for this placement is UOB Kay Hian Private Limited. For further information, investors can contact Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.

Conclusion: Why This News Is Potentially Price-Sensitive

The approval for listing and quotation of new shares is a major corporate action that could influence iX Biopharma’s share price due to dilution effects and potential investor sentiment around the company’s strategic direction. The successful completion of the placement could provide the company with new funds to pursue growth opportunities, but shareholders should be mindful of the risks and uncertainties until the placement is finalized.

Disclaimer

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. Investors should consult their own advisors and perform their own due diligence before making any investment decisions. The Singapore Exchange Securities Trading Limited has not reviewed or approved the content of this article.

View IX BiopharmaW260718 Historical chart here